Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05195164
Other study ID # 20-2141
Secondary ID NIH 5 K12 HD0570
Status Recruiting
Phase
First received
Last updated
Start date March 22, 2021
Est. completion date March 2024

Study information

Verified date March 2023
Source University of Colorado, Denver
Contact Sean Iwamoto, MD
Phone 303-724-8534
Email sean.iwamoto@cuanschutz.edu
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study plans to learn more about differences in heart disease risk after gender-affirming orchiectomy (i.e., testes removal) in older transgender (trans) women compared to younger trans women.


Description:

The global aim of this study is to characterize cardiometabolic risk (measured by vascular, metabolic and biochemical factors-which have not been extensively studied prospectively) in trans women before and after orchiectomy. Trans women appear to be at greater risk for cardiovascular disease (CVD) and blood clots compared to non-trans adults. The effect of orchiectomy on CVD risk among trans women is unknown, but orchiectomy may change blood vessel function and metabolic health. The investigators will examine blood vessel function and metabolic profiles of trans women before and at several timepoints after orchiectomy to identify age-related differences in CVD risk factors. This knowledge may lead to new approaches to prevent CVD in trans women as well as all people regardless of gender identity.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date March 2024
Est. primary completion date March 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria: - Aged 18 years and older - Identify as a transgender woman - Have taken estradiol and spironolactone for at least one year - Currently taking oral or transdermal or injectable estradiol - Have not yet undergone but desire orchiectomy Exclusion Criteria: - Under 18 years of age - Don't identify as a transgender woman - Not currently taking estradiol or spironolactone - Have been on estradiol and spironolactone for less than one year - History of orchiectomy - Not deemed a candidate for orchiectomy - Current tobacco smoker - Current illicit drug use - History of prior or active estrogen-dependent neoplasms - Acute liver or gallbladder disease - Venous thromboembolism - Hypertriglyceridemia >500 mg/dL - Fasted plasma glucose >7.0 mmol/L or previously treated diabetes - Resting blood pressure >140/90 mmHg

Study Design


Locations

Country Name City State
United States University of Colorado Aurora Colorado

Sponsors (2)

Lead Sponsor Collaborator
University of Colorado, Denver National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluation of endothelial function (flow-mediated dilation (FMD) at Baseline Brachial artery flow-mediated dilation (FMD), as measured by ultrasound. Baseline
Primary Evaluation of endothelial function (flow-mediated dilation (FMD) at 1 Month Brachial artery flow-mediated dilation (FMD), as measured by ultrasound. 1 month
Primary Evaluation of endothelial function (flow-mediated dilation (FMD) at 6 Months Brachial artery flow-mediated dilation (FMD), as measured by ultrasound. 6 month
Primary Evaluation of endothelial function (flow-mediated dilation (FMD) at 12 Months Brachial artery flow-mediated dilation (FMD), as measured by ultrasound. 12 month
Secondary Evaluation of carotid artery compliance The carotid artery compliance index indicates how elastic the artery is. The index describes the change in arterial blood volume in response to a change in arterial blood pressure. Lower numbers are associated with worse outcomes (less elastic arteries). Baseline, 1 mo., 6 mo., 12 mo.
Secondary Evaluation of carotid artery beta stiffness index The carotid artery beta stiffness index indicates how stiff the artery is. Higher numbers are associated with worse outcomes (stiffer artery). Baseline, 1 mo., 6 mo., 12 mo.
Secondary Carotid artery intimal-medial thickness Baseline, 1 mo., 6 mo., 12 mo.
Secondary Evaluation of oxidant burden: oxidized LDL Oxidized low-density lipoprotein (LDL) measured in the blood and endothelial cells. Baseline, 1 mo., 6 mo., 12 mo.
Secondary Evaluation of oxidant burden: nitrotyrosine Nitrotyrosine measured in the blood and endothelial cells. Baseline, 1 mo., 6 mo., 12 mo.
Secondary Evaluation of vascular endothelial cell inflammation: nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB) Protein NFkB (nuclear factor kappa-light-chain-enhancer of activated B cells) measured in blood and endothelial cells. Baseline, 1 mo., 6 mo., 12 mo.
Secondary Evaluation of vascular endothelial cell inflammation: MCP-1 Monocyte Chemoattractant Protein-1 (MCP-1) measured in blood and endothelial cells. Baseline, 1 mo., 6 mo., 12 mo.
Secondary Evaluation of vascular endothelial cell inflammation: IL-6 Interleukin 6 (IL-6) measured in blood and endothelial cells. Baseline, 1 mo., 6 mo., 12 mo.
Secondary Evaluation of vascular endothelial cell inflammation: CRP C-reactive protein (CRP) measured in blood and endothelial cells. Baseline, 1 mo., 6 mo., 12 mo.
Secondary Blood pressure Blood pressure will be measured at baseline, 1 mo., 6 mo. 12 mo. Baseline, 1 mo., 6 mo., 12 mo.
Secondary Plasma lipid concentrations: total cholesterol Total cholesterol will be determined at baseline, 1 mo., 6 mo., 12 mo. Baseline, 1 mo., 6 mo., 12 mo.
Secondary Plasma lipid concentrations: triglycerides Triglycerides will be determined at baseline, 1 mo., 6 mo., 12 mo. Baseline, 1 mo., 6 mo., 12 mo.
Secondary Insulin sensitivity Baseline, 1 mo., 6 mo., 12 mo.
Secondary Whole body composition: Percent Lean Mass Percent lean mass will be determined using dual energy x-ray absorptiometry. Baseline, 6 mo., 12 mo.
Secondary Whole body composition: Percent Fat Mass Percent fat mass will be determined using dual energy x-ray absorptiometry. Baseline, 6 mo., 12 mo.
Secondary Regional body composition: Percent Lean Mass Regional percent lean mass will be determined using dual energy x-ray absorptiometry. Baseline, 6 mo., 12 mo.
Secondary Regional body composition: Percent Fat Mass Regional percent fat mass will be determined using dual energy x-ray absorptiometry. Baseline, 6 mo., 12 mo.
Secondary Bone density Bone density of femur and spine will be determined using dual energy x-ray absorptiometry. Baseline, 12 mo.
Secondary Weight changes Body weight will be measured at baseline, 1 mo., 6 mo., 12 mo. Baseline, 1 mo., 6 mo., 12 mo.
Secondary Appetite ratings Baseline, 1 mo., 6 mo., 12 mo.
Secondary Appetite-related peptides Baseline, 1 mo., 6 mo., 12 mo.
Secondary D-Dimer Baseline, 1 mo., 6 mo., 12 mo.
Secondary Alcohol use Baseline, 1 mo., 6 mo., 12 mo.
Secondary Depression symptoms Baseline, 1 mo., 6 mo., 12 mo.
Secondary Physical activity monitoring Physical activity will me monitored for 7 days with an ActivPAL monitor 7 days at baseline, 1 mo., 6 mo., 12 mo.
Secondary Energy intake Energy intake will be estimated with a 3-day food diary 3 days at baseline, 1 mo., 6 mo., 12 mo.
Secondary Sex hormone concentrations Sex hormone concentrations of estradiol, testosterone, follicle stimulating hormone (FSH), luteinizing hormone (LH) and sex hormone-binding globulin (SHBG) will be measured Baseline, 1 mo., 6 mo., 12 mo.
See also
  Status Clinical Trial Phase
Completed NCT03255187 - Effect of Dietary Supplemental Fish Oil in Alleviating Health Hazards Associated With Air Pollution N/A
Completed NCT05997303 - Continuous Norepinephrine Administration and Blood Pressure Stability During Anesthetic Induction N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT03918486 - Caretaker vs. Routine Blood Pressure Sphygmomanometer
Completed NCT03410342 - The Effects of Types of Fruits and Vegetables on Vascular Function N/A
Active, not recruiting NCT05062161 - Sleep Duration and Blood Pressure During Sleep N/A
Not yet recruiting NCT04087070 - Blood Pressure Estimation Using Noninvasive Biosignals During Pediatric Anesthesia
Completed NCT03294928 - Arterial Waveform Analysis Applying Different Positive End-Expiratory Pressure (PEEP) Levels in Healthy Volunteers N/A
Completed NCT03859934 - Metabolic Effects of Melatonin Treatment Phase 1
Completed NCT03997461 - Comparison of Arterial Tonometry Sensor With Standard Oscillometric Blood Pressure Monitoring Device N/A
Completed NCT03290716 - Diet, ExerCIse and carDiovascular hEalth (DECIDE) - Salt Reduction Strategies for the Elderly in Nursing Homes in China N/A
Recruiting NCT06460233 - Blood Pressure Changes After Bariatric Surgery
Recruiting NCT05196048 - Blood Pressure Sensor of Watch-type Device With ECG Technology
Terminated NCT03325933 - Resistance Training and Cardiometabolic Health N/A
Not yet recruiting NCT06405880 - Pharmacist Case Finding and Intervention for Vascular Prevention Trial N/A
Completed NCT02924454 - Effects of Lipid Emulsion on the Pharmacokinetic and Pharmacodynamic Properties of Metoprolol. Phase 4
Completed NCT02451059 - Reducing Socioeconomic Disparities in Health at Pediatric Visits N/A
Active, not recruiting NCT02670967 - Effects of Soluble Fiber on Blood Pressure: A Meta-analysis of Randomly-controlled Trials N/A
Completed NCT02239744 - Intervention Study on the Health Impact of Air Filters in Chinese Adults N/A
Completed NCT02271633 - Nitrate Supplementation; Source Phase 4